While less dramatic than the changes seen with CA125 or Mesothelin, reduced Enolase 2 expression reflects an impact on tumor metabolism, essential for cancer cell survival, proliferation, and adaptation to therapy. This evidence concerns the gene MSLN and neoplasm.